Skip to main content

Table 3 Overall survival and patient characteristics of the entire patient population (n = 1106) and the diabetic patient population (n = 186)

From: Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer

  Entire Patient Population (n = 1106) Diabetic Patient Population (n = 186)
Characteristic OS (m)
n
95 % CI p OS (m)
n
95 % CI p
Gender    <0.0001    0.087
 Female 23.0
520
19.2–26.8   26.9
86
13.5–40.4  
 Male 14.9
586
13–16.9   14.3
100
12–16.5  
Age    0.369    0.926
 ≤61 18.7
544
16.6–20.9   16.4
59
12.2–20.7  
 > 61 17.4
562
12.8–22   18.3
127
7.3–29.2  
Smoking history    0.01    0.065
 No 23.8
456
20.1–27.4   27.3
82
22.8–31.9  
 Yes 15.2
650
13.4–17   13.8
104
11.8–15.9  
Histology    0.089    0.678
 Other 14.2
352
11.1–17.2   14.9
60
10.3–19.6  
 Adenocarcinoma 20.2
754
17.4–23   16.4
126
7.5–25.4  
Stage    <0.0001    0.012
 II-IIIa 38.5
63
17.3–59.7   61.1
12
 
 IIIb-IV 17.2
1043
14.8–19.6   15.2
174
12.8–17.6  
Diabetes    0.619    
 Yes 18.5
186
16.2–20.7     
 No 16.4
920
8.3–24.5     
Metformin use    0.046    0.017
 No 18.3
995
15.9–20.6   13.2
75
12.0–14.5  
 Yes 25.6
111
13.7–37.6   25.6
111
13.7–37.6  
Insulin use    0.743    0.718
 No 19
1087
16.4–20.4   17.0
165
8.4–25.6  
 Yes 15.8
19
8.6–22.9   15.8
21
8.6–23.0  
Glibenclamide use    0.703    0.473
 No 18.4
1046
16.4–20.5   17.0
126
5.2–28.7  
 Yes 15.2
60
9.8–20.3   15.2
60
9.8–20.6  
Glycemic control    <0.001    <0.0001
 Improper (≥130 mg/dLa) 12.1
208
10.1–14.1   13.2
127
12–14.4  
 Proper (<130 mg/dLa) 19.8
887
17.2–22.3   40.5
58
11.1–69.8  
Glycemic control and diabetesb    <0.001    
 Proper diabetic control 40.5
58
11.2–69.8     
 Improper diabetic control 13.2
127
11.9–14.4     
 Non-diabetic 18.4
920
16.2–20.8     
  1. OS Overall Survival, m Months
  2. a Calculated mean serum glucose b One patient with missing glucose values